High glucose stimulates TNF|[alpha]| and MCP-1 expression in rat microglia via ROS and NF-|[kappa]|B pathways
Yi Quan,Chang-tao Jiang,Bing Xue,Shi-gong Zhu,Xian Wang
DOI: https://doi.org/10.1038/aps.2010.174
IF: 7.169
2011-01-01
Acta Pharmacologica Sinica
Abstract:Inflammation plays a key role in central nervous system diseases. As the immune cells in the brain, microglia play an important role in the pathogenesis of central nervous system. In 2000, using nonradioactive in situ hybridization, Gregersen reported that microglia were one of the major sources of TNF after the induction of stroke in mice1. Glutamate was released by the oxygen and glucose deprivation-stressed neuron-astrocyte cultures, and then activated microglia by mGluRIIs to produce and release tumor necrosis factor (TNF)α, which induced neurotoxicity in this stroke model2. These results show that cytokines, such as TNFα, released by microglia contribute to the development of neuronal damage during a stroke. Other studies have suggested that microglia might be involved in the pathogenesis of Parkinson's disease. In the mesencephalic neuron-glia cultures, extracellular aggregated human α-synuclein activated microglia, and the activation of microglia enhanced dopaminergic neurodegeneration3. A loss of α-synuclein expression altered the morphology and inflammatory response of microglia and impaired microglial phagocytic ability4. Increased TNFα production from amyloid β-stimulated microglia led to elevated iNOS in astrocytes and neuronal apoptosis, illustrating that an increase in microglia-derived TNFα in response to amyloid β may be a contributor to neuron loss in Alzheimer's disease5. Moreover, the suppression of microglial derived TNFα and interleukin (IL)-1β by copolymer-1 diminished neurodegeneration in HIV-1 encephalitis6. Thus, inflammation induced by activated microglia is one of the major contributors to the pathogenesis of brain related diseases. Diabetes causes many complications, including retinopathy, nephropathy, and peripheral neuropathy. In addition, diabetes has a central nervous system complication, diabetic encephalopathy, which leads to direct neuronal damage7, 8. Apoptosis-induced neuronal loss and damage in type 1 diabetes is associated with cognitive impairment9. Although the mechanisms of neuronal apoptosis in diabetic encephalopathy have not been clearly studied, hyperglycemia is thought to be one of the most important factors10, 11, 12. An increased level of glucose in the brain induced by hyperglycemia leads to neuronal apoptosis and impaired cognition9, 12, 13, 14, 15. However, the effect of hyperglycemia on the activation of microglia and the role of inflammation in the pathogenesis of diabetic encephalopathy is still unclear. We previously reported that high glucose can activate microglia and significantly increase the secretion and mRNA expression of growth-regulated oncogene (GRO), a member of the IL-8 family, in rat microglia in vitro16. This finding suggests that in the central nervous system of patients with diabetes mellitus, high concentrations of glucose may induce microglial activation and the secretion of IL-8, thus contributing to the development of diabetic encephalopathy. In this study, we investigated the effect of high glucose on the inflammatory function of microglia. We found that compared with low glucose (10 mmol/L), high glucose (35 mmol/L) increased the secretion and mRNA expression of TNFα and monocyte chemoattract protein-1 (MCP-1) in rat microglia in vitro. Reactive oxygen species (ROS) and nuclear factor kappa B (NF-κB) pathways were involved in this process. However, there were no effects of high glucose on the secretion of IL-1β and IL-6. The level of MCP-1 in the culture medium was also determined by ELISA. MCP-1 secretion from high glucose-treated rat microglia increased in a time-dependent manner, with a final 1.5-fold increase compared to treatment with low glucose (Figure 1C). Incubation with mannitol for 24 h had no effect on MCP-1 secretion (Figure 1D). However, treatment with high glucose for 24 h had no effect on either IL-1β or IL-6 (Figure 1E, 1F) secretion compared with low glucose. Treatment with high glucose also induced MCP-1 mRNA expression in a time-dependent manner (Figure 2C). Rat microglia treated with high glucose for 3 h showed a 2-fold increase in MCP-1 mRNA expression compared to low glucose and an even higher increase after 6 h. Equimolar amounts of mannitol did not increase MCP-1 mRNA expression; thus, the high glucose-induced MCP-1 mRNA expression was also independent of osmotic pressure (Figure 2D). We have shown that high glucose increases the secretion and mRNA expression of TNFα and MCP-1 in rat microglia. These effects are specific to high glucose rather than hyperosmolality. ROS and NF-κB pathways mediate the high glucose-induced secretion of TNFα and MCP-1. However, high glucose has no effect on the secretion of IL-1β and IL-6 compared to low glucose. TNFα, a proinflammatory cytokine, is synthesized and released by microglia and can activate the caspase pathway, leading to neural apoptosis through the TNF receptor22, 23. It has been reported that fewer sympathetic and sensory neurons died during the phase of naturally occurring neuronal death in TNF-deficient embryos, and neurons from these embryos also survived in the culture better than wild-type neurons24. In addition to its role in apoptotic events, TNFα acts as a regulator of synaptic plasticity. Using TNFα knockout mice, Golan et al showed that TNFα may specifically suppress hippocampal function in adult mice through the suppression of NGF expression and dentate gyrus development25. MCP-1, one of the most important chemokines, plays a critical role in the migration of bone marrow derived and resident cells to sites of inflammation26. Huang et al found that MCP-1 null mice exhibited markedly reduced clinical and histological autoimmune encephalomyelitis (EAE) compared with wild-type animals. These results suggest that MCP-1 plays a crucial role in Th1 immune responses during EAE induction27. MCP-1 has been shown to inhibit HIV-tat and NMDA-induced apoptosis in mixed cultures of human neurons and astrocytes by reducing the extracellular levels of glutamate and regulating the intracellular trafficking of tat and NMDA receptor 1 expression in neurons. This finding suggests that MCP-1 may play a novel role as a protective agent against the toxic effects of glutamate and HIV-tat28. In the CNS of diabetic patients, high concentrations of glucose may induce microglial activation and the secretion of TNFα and MCP-1, thus contributing to the development of diabetic encephalopathy. Oxidative injury induced by high glucose concentrations plays a central role in the pathogenesis of diabetic complications29. Recent observations suggest that hyperglycemia-triggered ROS contribute to the development of diabetic nephropathy30, 31. High glucose-induced ROS activated NF-κB and increased MCP-1 production, which may cause macrophage recruitment and activation, resulting in diabetic renal injury32. In addition, the formation of oxygen-derived radicals led to the activation of NF-κB, which increased the expression of vascular cell adhesion molecule 1 and MCP-1 in human aortic endothelial cells. Thus, ROS-mediated NF-κB activation may play a role in the onset of atherosclerosis in diabetic patients33. The involvement of ROS and NF-κB in high glucose-induced apoptosis has also been demonstrated in cultured human endothelial cells34. We found that treatment with a high concentration of glucose induced ROS formation and that the ROS scavenger NAC significantly reduced the high glucose-induced secretion of TNFα and MCP-1. Furthermore, the NF-κB inhibitors MG132 and PDTC completely prevented the high glucose-induced TNFα and MCP-1 secretion. Thus, ROS and NF-κB pathways mediate high glucose-induced secretion of TNFα and MCP-1 from rat microglia. In conclusion, in our diabetic model, microglia are activated by high glucose treatment to produce ROS, which, in turn, activate the transcription factor NF-κB. Activation of NF-κB leads to the transcription of TNFα and MCP-1, resulting in an increased expression of TNFα and MCP-1. The release of inflammatory TNFα and MCP-1 by microglia may be involved in the pathogenesis of neuronal injury in diabetic encephalopathy. Overall, our study demonstrates that microglia might be a new target for the treatment of diabetic encephalopathy. Most experiments were done by Yi QUAN and she also wrote the paper. Chang-tao JIANG, Bing XUE, and Shi-gong ZHU did some of the experiments. Xian WANG and Yi QUAN designed the experiments together. This study was supported by the Major National Basic Research Program of China (No 2006CB503802) and the Program for Changjiang Scholars and Innovative Research Team in Universities, as well as the National Natural Science Foundation of China (No 30330250) awarded to Xian WANG.